Themis Medicare Ltd
Themis Medicare Q4 FY24 earnings call: Revenue & Margins
Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹98Cr
- +22.1% YoY
- Net profit
- ₹7Cr
- −21% YoY
- Margin
- 9.5%
- −3.6 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Themis Medicare Ltd Q4 FY24 key numbers
- Revenue
- FY24 Net Revenue: Rs. 381.76 Cr, up 7.74% YoY from Rs. 354.32 Cr in FY23.
As stated in Themis Medicare Ltd's Q4 FY24 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Themis Medicare Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY24 Net Revenue: Rs. 97.82 Cr, up 22.11% YoY from Rs. 80.10 Cr in Q4 FY23 (Page 8). Quarterly EBITDA (Q4 FY24): Rs. 9.30 Cr, down 11.30% YoY from Rs. 10.48 Cr.
From Themis Medicare Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY24 Net Revenue: Rs. 97.82 Cr, up 22.11% YoY from Rs. 80.10 Cr in Q4 FY23 (Page 8)
- Hospital Business grew over 21% YoY for FY24 (Page 8)
- FY24 Net Revenue: Rs. 381.76 Cr, up 7.74% YoY from Rs. 354.32 Cr in FY23 (Page 9)
- EBITDA margin for Q4 FY24 declined by 358 bps YoY due to production halts and investment (Page 8)
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Themis Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q4 FY24 results — key figures
| ₹ Cr | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 98 | 80 | +22.1% | 83 | +18.6% |
| Operating profit (EBITDA) | 9 | 10 | -11.4% | 8 | +15.4% |
| Operating margin | 9.5% | 13.08% | -3.6 pp | 9.76% | -0.3 pp |
| Profit before tax | 9 | 10 | -15.1% | 8 | +6.5% |
| Net profit (PAT) | 7 | 8 | -21% | 7 | -9.9% |
| EPS (₹) | 0.72 | 0.91 | -20.9% | 0.80 | -10% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY24)
1,759 Cr, a 5% YoY increase from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Bharat Parenterals (Q4 FY24)
For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Key concall takeaways from Bharat…
- Fermenta Biotech (Q4 FY24)
Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) . Key concall takeaways from Fermenta Biotech Ltd's Q4 FY24 earnings call — and…
- Amrutanjan Healt (Q4 FY24)
OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) . Key concall takeaways from Amrutanjan Health Care Ltd's Q4 FY24 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q4 FY24 results?
Q4 FY24 Net Revenue: Rs. 97.82 Cr, up 22.11% YoY from Rs. 80.10 Cr in Q4 FY23 (Page 8). Quarterly EBITDA (Q4 FY24): Rs. 9.30 Cr, down 11.30% YoY from Rs. 10.48 Cr.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.